%I American Society for Clinical Investigation
%A A Ogbe
%A M Pace
%A M Bittaye
%A T Tipoe
%A S Adele
%A J Alagaratnam
%A PK Aley
%A MA Ansari
%A A Bara
%A S Broadhead
%A A Brown
%A H Brown
%A F Cappuccini
%A P Cinardo
%A W Dejnirattisai
%A KJ Ewer
%A H Fok
%A PM Folegatti
%A J Fowler
%A L Godfrey
%A AL Goodman
%A B Jackson
%A D Jenkin
%A M Jones
%A S Longet
%A RA Makinson
%A NG Marchevsky
%A M Mathew
%A A Mazzella
%A YF Mujadidi
%A L Parolini
%A C Petersen
%A E Plested
%A KM Pollock
%A T Rajeswaran
%A MN Ramasamy
%A S Rhead
%A H Robinson
%A N Robinson
%A H Sanders
%A S Serrano
%A T Tipton
%A A Waters
%A P Zacharopoulou
%A E Barnes
%A S Dunachie
%A P Goulder
%A P Klenerman
%A GR Screaton
%A A Winston
%A AVS Hill
%A SC Gilbert
%A M Carroll
%A AJ Pollard
%A S Fidler
%A J Fox
%A T Lambe
%A J Frater
%X Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.
%O Copyright: © 2022, Ogbe et al. This is an open access article published under the terms of the Creative CommonsAttribution 4.0 International License.
%D 2022
%T Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
%L discovery10184137
%K AIDS/HIV, Adaptive immunity, COVID-19, Cellular immune response, T cells, COVID-19, ChAdOx1 nCoV-19, HIV Infections, Humans, Male, SARS-CoV-2, Vaccination
%V 7
%C United States
%N 7
%J JCI Insight